When Unexpected Particles Threaten Your Biologic

Unexpected particle findings can raise critical questions about product quality, patient safety, and regulatory compliance.

Join KBI Biopharma’s experts to learn how clinical in-use studies and advanced particle forensics can help identify particle sources, assess risk, and build regulator-ready evidence for confident decision-making.

Register now to discover practical strategies for accelerating investigations, supporting development timelines, and responding effectively when unexpected particles threaten your biologic.